- Bay Area Times
- Posts
- Tirzepatide for weight loss (Zepbound) approved by FDA, has higher efficacy vs. Ozempic
Tirzepatide for weight loss (Zepbound) approved by FDA, has higher efficacy vs. Ozempic
Bay Area Times
November 09, 2023
Brought to you by:
Top stories today:
- Tirzepatide for weight loss (Zepbound) approved by FDA
- Humane AI Pin to be launched today, likely $699 + $24/mo
- GitHub announces Copilot Enterprise for $39/mo, out in Feb.
- Israel: U.S. strikes Syria, negotiating 3-day pause for 15 hostages
- NASA Plus, free streaming service, launches
- U.S. population to peak at 370M in 2080: Census projection
0. Data and calendar
All values as of 6 AM ET / 3 AM PT, other than S&P500 close (4 PM ET / 1 PM PT).
All times are ET.
1. Tirzepatide for weight loss (Zepbound) approved by FDA, has higher efficacy vs. Ozempic
Its U.S. list price is $1,060, around its main competitors
End-of-year: expected launch. - FDA
Restaurants are betting these drugs will increase sales of healthier foods.
2. Humane AI Pin to be launched today, likely $699 + $24/mo
$24/mo includes a phone number and cell data on T-Mobile.
Uses OpenAI and Microsoft models.
Comes with 2 “battery boosters” which can be swapped in.
Used by the Bay Area Times team.
One-click install, as a Chrome extension.
5.0 stars on the Chrome Web Store.
#1 product of the day (Product Hunt)
*Sponsored.
